Jose Carmona Acquires 3,000 Shares of Radius Health, Inc. (RDUS) Stock
Radius Health, Inc. (NASDAQ:RDUS) CFO Jose Carmona acquired 3,000 shares of Radius Health stock in a transaction on Thursday, September 14th. The stock was purchased at an average price of $32.83 per share, with a total value of $98,490.00. Following the transaction, the chief financial officer now directly owns 3,000 shares in the company, valued at approximately $98,490. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Radius Health, Inc. (RDUS) traded up 1.67% during midday trading on Friday, reaching $33.54. The company had a trading volume of 2,913,154 shares. Radius Health, Inc. has a 12 month low of $31.58 and a 12 month high of $59.22. The firm has a 50-day moving average of $37.54 and a 200-day moving average of $39.19. The stock’s market cap is $1.46 billion.
Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.23). The business had revenue of $0.98 million during the quarter, compared to analysts’ expectations of $1.96 million. During the same period in the previous year, the firm earned ($1.01) EPS. On average, equities analysts expect that Radius Health, Inc. will post ($5.58) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/15/jose-carmona-acquires-3000-shares-of-radius-health-inc-rdus-stock.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. DUPONT CAPITAL MANAGEMENT Corp bought a new stake in Radius Health during the first quarter worth $304,000. State of Wisconsin Investment Board bought a new stake in Radius Health during the second quarter worth $1,176,000. OppenheimerFunds Inc. lifted its stake in Radius Health by 0.3% during the first quarter. OppenheimerFunds Inc. now owns 301,631 shares of the biopharmaceutical company’s stock worth $11,658,000 after purchasing an additional 831 shares during the last quarter. American International Group Inc. lifted its stake in Radius Health by 7.1% during the first quarter. American International Group Inc. now owns 19,430 shares of the biopharmaceutical company’s stock worth $751,000 after purchasing an additional 1,284 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in Radius Health during the first quarter worth $241,000.
Several equities analysts recently commented on the company. Cantor Fitzgerald set a $65.00 target price on Radius Health and gave the stock a “buy” rating in a research report on Monday, May 22nd. Maxim Group set a $24.00 target price on Radius Health and gave the stock a “sell” rating in a research report on Wednesday, May 24th. Zacks Investment Research downgraded Radius Health from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Canaccord Genuity restated a “buy” rating and set a $85.00 target price on shares of Radius Health in a research report on Monday, May 22nd. Finally, BidaskClub upgraded Radius Health from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $53.60.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.